Rubicon Research Pvt Ltd has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for
Tizanidine Hydrochloride Capsules, in the strengths of 2 mg (base), 4 mg (base), and 6 mg (base). Tizanidine hydrochloride is a
central alpha-2-adrenergic agonist indicated for the management of spasticity.
Rubicon Research Pvt Ltd has received approval from the US Food and Drug Administration for its Abbreviated New Drug
Application for Amantadine Capsules USP in the strength of 100 mg. Amantadine Hydrochloride, USP, is indicated
for prophylaxis, and for the treatment of signs and symptoms of infection caused by various strains of influenza
A virus, Parkinsonism, and drug-induced extrapyramidal reactions.
Rubicon Research Pvt Ltd has committed Rs 2 crore to support India’s fight against the coronavirus pandemic.
The support will be by way of a number of initiatives, including donating Rs 1.9 crore worth of Hydroxychloroquine
(1.5 million tablets) and immunity boosting products to help frontline workers and high-risk patients.
As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited,
a leading specialty pharmaceutical company, today announced the acquisition of Impopharma Canada Limited
with operations in Ontario, Canada.
Rubicon announces offering of analytical services as standalone activity from its cGMP plant location. We base our approach on our expertise
in Analytical Method Development and GMP Quality Control Testing. This service supplements our stability storage and stability samples analysis
service from well controlled stability study infrastructure.
Rubicon Research Pvt Ltd (“Rubicon”), a global leader in innovative pharmaceutical product development, announced today that General Atlantic
has become a significant shareholder in the company. General Atlantic, a leading global growth equity firm, is committing up to $100 million
of primary capital and has acquired the stake held by Rubicon’s existing private equity shareholders. All other existing shareholders
continue to maintain their shareholding in the company.